Searched for
QIDP
Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check detailsWockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections....
- Habil Khorakiwala on 3 things in the pipeline that can cause a re-rating for WockhardtHabil Khorakiwala says: “We have earlier signed an agreement on a profit-sharing basis for contract manufacturing with Serum Institute to m...
- View: Covid vaccine development is Indian pharma's shot at global fameThe experience with Covid vaccine development has provided India a unique opportunity to burnish its credentials as a global leader in the ...
- Wockhardt gets QIDP designation from USFDA for its combination antibioticThe QIDP status is granted to drugs that are effective against a set of multi-drug resistant pathogens identified by the Centre for Disease...
- Wockhardt sets up its first manufacturing facility in Middle East"With the new facility in the Middle East, we aim to focus on our commitment to developing NCEs to fight the health issues," Wockhardt Foun...
- Drug maker Wockhardt on fast track of innovationThe renewed optimism in the global outlook for anti-infective products vindicates the company’s long-term strategy.
- Wockhardt gets QIDP status for new antibiotic product from FDAQIDP status is granted to drugs identified by Centre for Disease Control, US, that act against pathogens which have a high degree of unmet ...
- Wockhardt to enhance R&D capabilities in drug innovation: MDPharma firm Wockhardt will continue to strengthen its R&D capabilities to develop innovative and technologically advanced medicines, a top ...
- Wockhardt gets QIDP status for pneumonia drug from USFDAWockhardt today said a product from its new drug discovery programme, which aims to treat pneumonia, has received QIDP status from the US h...
- Wockhardt Ltd rallies on receiving QIDP status for two drugsThis is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued.
- Nifty breaches 8,000-mark for first time, Sensex hits new peak; top 15 stocksThe 50-share NSE Nifty index breached the 8,000-mark for the first time ever in trade on Monday and BSE Sensex logged a new peak of 26,854....
- Fifteen stocks in focus in Monday morning tradeThe 50-share Nifty index surged over 40 points to hit its fresh record high of 8,007.95, led by gains in NTPC, Coal India, Hindalco, L&T an...
- Wockhardt's WCK 771 and WCK 2349 recieve QIDP status from US FDAThis is the first instance of an Indian pharmaceutical company receiving a QIDP status, Wockhardt said in a release issued here.
- USFDA grants Qualified Infectious Disease Product status to two Wockhardt drugsTwo drugs - WCK 771 and WCK 2349 - have received QIDP status, which allows fast-track review of the drug application by the USFDA.
Load More
